Stephen Garbacz

Corporate Officer/Principal at Tessera Therapeutics, Inc.

65 year

Health Technology

Consumer Services

Profile

Stephen Garbacz is currently the Head of Finance at Tessera Therapeutics, Inc. He previously worked as the CAO and Executive Director of Finance at Epizyme, Inc. in 2012.
From 2019 to 2021, he was the Vice President of Finance and Corporate Controller at Anika Therapeutics, Inc. Prior to that, he was the Senior Vice President of Finance and Operations at Spero Therapeutics, Inc. Mr. Garbacz received his undergraduate degree from George Mason University and his MBA from The Leonard N Stern School of Business.

Stephen Garbacz active positions

Companies	Position	Start
Tessera Therapeutics, Inc. Tessera Therapeutics, Inc. BiotechnologyHealth Technology Tessera Therapeutics, Inc. engages in science company. It offers scientists and doctors the ability to write and rewrite small and large therapeutic messages into the genome, thereby curing diseases at their source. The company is headquartered in Cambridge, MA.	Corporate Officer/Principal	2021-04-30

All active positions of Stephen Garbacz

Former positions of Stephen Garbacz

Companies	Position	End
ANIKA THERAPEUTICS, INC.	Comptroller/Controller/Auditor	2021-04-30
SPERO THERAPEUTICS, INC.	Chief Operating Officer	-
EPIZYME, INC.	Director of Finance/CFO	-

See the detail of Stephen Garbacz's experience

Training of Stephen Garbacz

George Mason University	Undergraduate Degree
The Leonard N Stern School of Business	Masters Business Admin

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Stephen Garbacz's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	2
ANIKA THERAPEUTICS, INC.	Health Technology
SPERO THERAPEUTICS, INC.	Health Technology

Private companies	2
Epizyme, Inc. Epizyme, Inc. BiotechnologyHealth Technology Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA.	Health Technology
Tessera Therapeutics, Inc. Tessera Therapeutics, Inc. BiotechnologyHealth Technology Tessera Therapeutics, Inc. engages in science company. It offers scientists and doctors the ability to write and rewrite small and large therapeutic messages into the genome, thereby curing diseases at their source. The company is headquartered in Cambridge, MA.	Health Technology